CTOs on the Move


 
Noom is the world`s leading behavior change company, disrupting the weight loss and healthcare industries. By combining the power of artificial intelligence, mobile tech, and psychology with the empathy of over 1,000 personal coaches, Noom helps people live healthier lives by changing their long-term habits. More than 50 million people have benefited from Noom`s behavior change courses, including its virtual diabetes prevention program, which was the first of its kind to be recognized by the CDC. The Noom platform is already being used by leading healthcare and pharmaceutical companies to improve treatment outcomes for patients worldwide. The company is headquartered ...
  • Number of Employees: 1K-5K
  • Annual Revenue: > $1 Billion
  • www.noom.com
  • 229 West 28th Street Floor 9
    New York, NY USA 10001
  • Phone: 800.910.7375

Executives

Name Title Contact Details
James Zhou
Chief Information Security Officer and Senior Director, Systems Operations Profile
Takeaki Chijiiwa
Director, Information Security Profile
Richard Friedman
Chief Technology Officer Profile

Funding

Noom raised $58M on 05/06/2019
Noom raised $540M on 05/25/2021

Similar Companies

BlackSea Technologies

BlackSea Technologies is a naval technology firm that enables new asymmetric strategies so U.S. Naval and military forces can prevail over the next several decades in multi-dimensional conflicts.

Mission Internal Medical Group

Mission Internal Medical Group Incorporated is a Laguna Hills, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Accord BioPharma

Foresee is a Taiwan and US-based biopharmaceutical company listed on the Taipei Exchange (6576.TWO). Foresee`s R&D efforts are focused in two key areas, namely its unique stabilized injectable formulation (SIF) depot delivery technology with derived drug products targeting specialty markets, and secondly its transformative preclinical and clinical first-in-class NCE programs targeting rare and severe disease areas with high unmet needs. Foresee`s product portfolio includes late stage and early stage programs. CAMCEVI® 42 mg is now approved in the U.S. and under regulatory review in the EU. Additionally, U.S. and EU regulatory submissions are in preparation for CAMCEVI® 21 mg. FP-025 – a highly selective oral MMP-12 inhibitor targeting inflammatory and fibrotic diseases, currently in Phase 2/3 studies, including a Phase 2/3 study for COVID-19 virus-induced acute respiratory distress syndrome (ARDS). FP-045 – a highly selective oral small molecule allosteric activator of ALDH2, a mitochondrial enzyme, for which a Phase 1b/2 study is currently planned for Fanconi Anemia.

Simplex Diabetic Supply Inc.

Simplex Diabetic Supply Inc. is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Brentwood, TN. To find more information about Simplex Diabetic Supply Inc., please visit www.simplexdiabetes.com

DocComply

DocComply is a Cedar Grove, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.